Clinuvel Pharmaceuticals (CUVL) Stock
Clinuvel Pharmaceuticals's price implies about 6% free cash flow growth a year.
Key numbers
- P/E (trailing)
- 11.2x
- EV / EBITDA
- 7.44x
- Revenue growth
- +5.2%
- Operating margin
- 43.4%
- Debt / equity
- 0.00x
What Clinuvel Pharmaceuticals's price implies
From a reverse DCF on Clinuvel Pharmaceuticals's SEC filings.
- Free cash flow, last 2 years
- -23.2%a year
- Revenue, same period
- 5.4%a year
At a market value of $260M, Clinuvel Pharmaceuticals's free cash flow of $12M (fiscal 2026) would need to grow about 6% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 2 years. A 9% discount rate and 3% growth after year 10 (how it works). Change them in the Modeling tab or the reverse DCF calculator.
Revenue and free cash flow
Fiscal years, from Clinuvel Pharmaceuticals's 10-K filings.
Clinuvel Pharmaceuticals revenue and free cash flow
FY2024–FY2026Results from SEC filings
All three statements · Quarters, TTM and 20+ years of statements in Investingly
| Fiscal year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | $58M | $61M | $64M |
| Net income | $23M | $23M | $23M |
| Free cash flow | $20M | $27M | $12M |
| EPS (diluted) | $0.46 | $0.46 | $0.46 |
| Operating margin | 49.3% | 43.4% | 43.4% |
Where the revenue comes from
By products, fiscal 2026. By year
Superinvestors who own CUVL
From each investor's latest 13F filing (what a 13F shows).
None of the superinvestors we track held CUVL in their latest 13F.
Clinuvel Pharmaceuticals insider buying
Open-market purchases by executives and directors in the last 12 months, from SEC Form 4 filings (what insider buying tells you).
No open-market insider purchases of CUVL in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.
Fundamental grade
Five factors scored 1 to 9 from CUVL's latest numbers. It describes the business, not whether the stock is a buy.
Get an alert at your buy price
Free accounts get 3 price alerts.
How Clinuvel Pharmaceuticals compares
Clinuvel Pharmaceuticals's P/E is higher than 20% of Healthcare companies and 21% of the 2,508 companies with a P/E figure.
| Higher than | Healthcare | All stocks |
|---|---|---|
| P/E | 20% | 21% |
| P/FCF | 50% | 66% |
| Revenue growth | 38% | 37% |
| Operating margin | 97% | 95% |
| ROE | 79% | 64% |
Questions about Clinuvel Pharmaceuticals
What growth does Clinuvel Pharmaceuticals's stock price imply?
At a market value of $260M, Clinuvel Pharmaceuticals would need its free cash flow to grow about 6% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 2 years its free cash flow grew -23% a year.
Are Clinuvel Pharmaceuticals insiders buying the stock?
No open-market insider purchases of CUVL in the last 12 months, according to SEC Form 4 filings.
Companies like Clinuvel Pharmaceuticals
Bicycle Therapeutics Ltd (BCYC)$259MLineage Cell Therapeutics Inc (LCTX)$266MArcturus Therapeutics Holdings Inc (ARCT)$267MLarimar Therapeutics, Inc. (LRMR)$268MVanda Pharmaceuticals Inc. (VNDA)$252MRocket Pharmaceuticals, Inc. (RCKT)$272MPrecision BioSciences Inc (DTIL)$273MAlector Inc (ALEC)$273MImmuneering Corp (IMRX)$246M All Healthcare stocks→Prices and ratios as of Nov 10, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.